Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation

Biochemical Pharmacology

Volumn 53, Issue 2, 1997, Pages 245-247

  Beltran, Pedro J ^a   Fan, Dominic ^a   Fidler, Isaiah J ^a   O'Brian, Catherine A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

drug accumulation; MDR reversal; multidrug resistance; PKC; staurosporine derivative

Indexed keywords

DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN P; MIDOSTAURIN; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; STAUROSPORINE DERIVATIVE; VINBLASTINE; VINCRISTINE;

ARTICLE; BREAST CANCER; CELL LINE; COLON CANCER; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; HUMANS; MICE; P-GLYCOPROTEIN; PHOSPHORYLATION; PROTEIN KINASE C; STAUROSPORINE; TUMOR CELLS, CULTURED;

EID: 0031012175     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00718-6     Document Type: Article

References (19)

1. Juliano RL and Ling V, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162, 1976.
2. Bradley G, Juranka PF and Ling V, Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87-128, 1988.
3. Fan D, Beltran PJ and O'Brian CA, Reversal of multidrug resistance. In: Reversal of Multidrug Resistance in Cancer (Ed. Kellen JA), pp. 93-125. CRC Press, Boca Raton, 1994.
4. O'Brian CA, Fan D, Ward N, Seid C and Fidler IJ, Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells. FEBS Lett 246: 78-82, 1989.
5. Posada JA, McKeegan EM, Worthington KF, Morin MJ, Jaken S and Tritton TR, Human multidrug resistant KB cells overexpress protein kinase C: Involvement in drug resistance. Cancer Commun 1: 285-292, 1989.
6. Gravitt KR, Ward NE, Fan D, Skibber JM, Levin B and O'Brian CA, Evidence that protein kinase C-α activation is a critical event in phorbol ester-induced multidrug resistance in human colon cancer cells. Biochem Pharmacol 48: 375-381, 1994.
7. Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki K, Tsuruo T, Cowan KH and Glazer RI, Transfection with protein kinase C-α confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 3: 181-189, 1991.
8. Bates SE, Lee JS, Dickstein B, Spolyar M and Fojo AT, Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry 32: 9156-9164, 1993.
9. Blobe GC, Sachs CW, Khan W A, Fabbro D, Stabel S, Wetsel WC, Obeid LM, Fine RL and Hannun YA, Selective regulation of expression of protein kinase C isoenzymes in multidrug-resistance MCF-7 cells. Functional significance of enhanced expression of PKC-α. J Biol Chem 268: 658-664, 1993.
10. Ma LD, Marquardt D, Takemoto L and Center MS, Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. J Biol Chem 266: 5593-5599, 1991.
11. Meyer T, Rehenass U, Fabbro D, Alteri E, Rosel J, Muller M, Carvatti G and Matter A, A derivative of staurosporine (CGP 41251) shows selectivity for PKC inhibition and in vitro antiproliferative as well as in vivo antitumor activity. Int J Cancer 43: 851-856, 1989.
12. Andrejauskas-Buchdunger E and Regenass U, Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res 52: 5353-5385, 1992.
13. Utz I, Hofer S, Regenass U, Hilbe W, Thaler J, Grunicke H and Hofmann J, The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int J Cancer 57: 104-110, 1994.
14. Corbett TH, Griswold DP Jr, Roberts BJ, Peckman JC and Schabel FM Jr, Tumor induction relationships in developing transplantable cancers of the colon in mice for chemotherapeutic assays with a note on carcinogen structure. Cancer Res 35: 2434-2439, 1975.
15. Fan D, Poste G, Ruffolo RR Jr, Dong Z, Seid C, Earnest LE, Campbell TE, Clyne RK, Beltran PJ and Fidler IJ, Circumvention of multidrug resistance in murine fibrosarcoma and colon carcinoma cells by treatment with the α-adrenoceptor antagonist furobenzazepine. Int J Oncol 4: 789-798, 1994.
16. Budworth J, Davies R, Malkhandi J, Gant TW, Ferry DR and Gescher A, Comparison of staurosporine and four analogues: Their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells. Br J Cancer 73: 1063-1068, 1996.
17. Sampson E, Wolff CL and Abraham I, Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance. Cancer Lett 68: 7-14, 1993.
18. Chaudhary PM and Roninson IB, Activation of MDR1 (Pglycoprotein) gene expression in human cells by protein kinase C agonists. Oncol Res 4: 281-290, 1992.
19. Killion JJ, Beltran P, O'Brian CA, Yoon S-S, Fan D, Wilson MR and Fidler IJ, The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251. Oncol Res 7: 453-459, 1995.